Clinical Trial Update: Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating liraglutide, a GLP-1 analogue, for antipsychotic-associated obesity and metabolic syndrome in schizophrenia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Obesity
• Schizophrenia

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: Bjorn H. Ebdrup | Conditions: Obesity, Metabolic Syndrome X | Phase 3 | Status: COMPLETED